We have looked at the IMS Health situation, whose share price dropped more than 18% on Friday 11-Dec-09 before recovering to an end of day price drop of 6%. The price dynamics were attributed to the amendment proposal to the Senate healthcare reform bill from 2 US senators, which effectively would limit the ability of drug companies like IMS Health to capture and use physician prescribing data. We believe that at the current $20 share price, the share is still oversold, and remain confident that the the deal at $22 will eventually go through in 1Q10.
Panta Capital's Idea Sample Blog is designed to share a limited sample of what Panta Capital considers as attractive event driven and special situation investment ideas & insights. Please contact us to gain access to the PANTA CLIENT SECTION, where you will gain full access to all attractive European and North-American situations and analyses.
Panta Capital's Idea Sample Blog is designed to share a limited sample of what Panta Capital considers as attractive event driven and special situation investment ideas & insights. Please contact us to gain access to the PANTA CLIENT SECTION, where you will gain full access to all attractive European and North-American situations and analyses.
